Литература

 Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., and Hiebert S.W., 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21: 6470-6483.

Baylin S.B., Fearon E.R., Vogelstein B., de Bustros A., Sharkis S.J., Burke P.J., Staal S.P., and Nelkin B.D., 1987. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 70: 412-417.

Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., and Herman J.G., 1998. Aberrant methylation of pl6^INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. 95: 11891-11896.

Brenner C., Deplus R., Didelot C., Loriot A., Vire E., De Smet C., Gutierrez A., Danovi D., Bernard D., Boon Т., et al., 2005. Мус represses transcription through recruitment of DNA methyltransferase compressor. EMBO J. 24. 336-346.

Burbee D.G., Forgacs E., Zochbauer Muller S., Shivakumar L., Fong K., Gao B., Randle D., Kondo M., Virmani A., Bader S., et al., 2001. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression./. Natl. Cancer Inst. 93: 691-699.

Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B., 1999. Synergy of demethylation and histone deacety-lase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21: 103-107.

Chen CM., ChenH.L., HsiauT.H., HsiauA.H., ShiH,, Brock G.J., Wei S.H., Caldwell C.W., Yan P.S., and Huang T.H., 2003. Methylation target array for rapid analysis of CpG island hypermethyla-tion in multiple tissue genomes. Am. J. Pathol. 163: 37-45.

Chen W., Cooper T.K., Zahnow C.A., Overholtzer M., Zhao Z., Ladanyi M., Karp J.E., Gokgoz N., Wunder J.S., Andrulis I.L., et al., 2004. Epigenetic and genetic loss of Hid function accentuates the role ofp53 in tumorigenesis. Cancer Cell 6: 387—398.

Chen W.Y, Wang D.H., Yen R.C., Luo J., Gu W, and Baylin S.B., 2005. Tumor suppressor HIC1 directly regulates S1RT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448.

Chen W.Y., Zeng X., Carter M.G.. Morrell C.N.. Chiu Yen R.W., Esteller M., Watkins D.N., Herman J.G., Mankowski J.L., and Baylin S.B., 2003. Heterozygous disruption of Hie /predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet. 33: 197-202.

Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., and Pfeifer G.P., 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25: 315-319.

Daskalakis M., Nguyen T.T., Nguyen C., Guldbeig P., Kohler G., Wijermans P., Jones P.A., and Lubbert M., 2002. Demethylation of a hypermethylated P15/INK4B gene in patients with my-elodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964.

Di Croce L., Raker V.A., Corsaro M., Fazi E, Fanelli M., Faretta M., Fuks E, Lo Coco E, Kouzarides T., Nervi C., et al., 2002. Methyl-transferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082.

Egger G., Liang G., Aparicio A., and Jones P.A., 2004. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.

Ehrlich M., Gama-Sosa M.A., Huang L.H., Midgett R.M., Kuo K.C., McCune R.A., and Gehrke C., 1982. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 10: 2709-2721.

Esteller M., Risques R.A., Toyota M., Capella G., Moreno V., Peinado M.A., Baylin S.B., and Herman J.G., 2001a. Promoter hypermethylation of the DNA repair gene 0(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumori-genesis. Cancer Res. 61: 4689-4692.

EstellerM., Fraga M.F., Guo M., Garcia-Foncillas J., HedenfalkL, Godwin A.K., Trojan J., Vaurs-Barriere C., Bignon Y.J., Ramus S., et al., 2001b. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10: 3001-3007.

Fahmer J.A., Eguchi S., Herman J.G., and Baylin S.B., 2002. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62: 7213-7218.

Feinberg A.P. and Vogelstein B., 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.

Feinberg A.P., Gehrke C.W., Kuo K.C., and Ehrlich M., 1988. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48: 1159-1161.

Finch P.W., He X.. Kelley M.J., Uren A.. Schaudies R.P., Popescu N.C., Rudikoff S., Aaronson S.A., Varmus H.E., and Rubin J.S., 1997. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl. Acad. Sci. 94: 6770-6775.

Flatau E., Bogenmann E., and Jones P.A., 1983. Variable 5-methylcy-tosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res. 43: 4901-4905.

Frost P., Liteplo R.G., Donaghue T.P., and Kerbel R.S., 1984. Selection of strongly immunogenic “turn” variants from tumors at high frequency using 5-azacytidine. J. Exp. Med. 159: 1491-1501.

Fuks E., Hurd P.J., Deplus R., and Kouzarides T., 2003. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31: 2305-2312.

Fuks E., Burgers W.A., Godin N., Kasai M., and KouzaridesT., 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J., 20: 2536-2544.

Gaudet E., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., GrayJ.W, Leonhardt H., and Jaenisch R., 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492.

Gazzoli I., Loda M., Garber J., Syngal S., and Kolodner R.D., 2002. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62: 3925-3928.

Grady W.M., Wilis J., Guilford P.J., Dunbier A.K., Toro T.T., Lynch H., Wesner G., Ferguson K., Eng C, Park J.G., et al., 2000. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 26: 16-17.

Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C., 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.

Gregorieff A. and Clevers H., 2005. Wnt signaling in the intestinal epithelium: From endoderm to cancer. Genes Dev., 19: 877-890.

Hanahan D. and Weinberg R.A., 2000. The hallmarks of cancer. Cell 100: 57-70.

Herman J.G. and Baylin S.B., 2003. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349: 2042-2054.

Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Wilson J.K., Hamilton S.R., Kinzler K.W, et al., 1998. Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci 95: 6870-6875.

Holm T.M., Jackson-Grusby L., BrambrinkT., Yamada Y, Rideout W.M., III, and Jaenisch R., 2005. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8: 275-285.

Holst C.R., Nuovo G.J., Esteller M., Chew K., Baylin S.B., Herman J.G., and Tlsty T. D., 2003. Methylation ofplG^lNK4a promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63: 1596-1601.

Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al., 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.

Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., and Baylin S.B., 1994. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon Nat. Genet. 7: 536-540.

Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., Bayar E., Lyons J., Rosenfeld C.S., Cortes J., and Kantaijian H.M. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.

Jones P.A., 1999. The DNA methylation paradox. Trends Genet. 15: 34-37.

Jones PA. and Baylin S.B., 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.

Jones P.A. and Laird P.W, 1999. Cancer epigenetics comes of age. Nat. Genet. 21: 163-167.

Jones P.A. and Taylor S.M., 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20: 85-93.

Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.-L., Leighton J.K., Patel H., Rahman A., Sridhara R., et al., 2005. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11: 3604-3608.

Kaneda A. and Feinberg A.P., 2005. Loss of imprinting of IGF2: A common epigenetic modifier of intestinal tumor risk. Cancer Res. 65: 11236-11240.

Katzenellenbogen R.A., Baylin S.B., and Herman J.G., 1999. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353.

Kinzler K.W. and Vogelstein B., 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761-763.

Kiyono T, Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J., 1998. Both Rb/pl6^INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.

Knudson A.G., 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162.

Kondo Y., Shen L., and Issa J.R, 2003. Critical role ofhistone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell. Biol. 23: 206-215.

Kuzmichev A., Margueron R., Vaquero A., PreissnerT.S., Scher M., KirmizisA., OuyangX., BrockdorffN., Abate-ShenC., Famham P., and Reinberg D., 2005. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. 102: 1859-1864.

Laird P.W., 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3: 253-266.

Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., and Jaenisch R., 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205.

Lapeyre J.N. and Becker F.F., 1979. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Commun. 87: 698-705.

Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., Hsieh W.S., Isaacs W.B., and Nelson W.G., 1994. Cytidine methylation of regulatory sequences near the xu-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. 91: 11733-11737.

Leu Y.W., Rahmatpanah F., Shi H., Wei S.H., Liu J.C., Yan P.S., and Huang T.H., 2003. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 63: 6110-6115.

Li E., Bestor T.H., and Jaenisch R., 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926.

Liu B., Nicolaides N.C., Markowitz S., Willson J.K., Parsons R.E., Jen J., Papadopolous N., Peltomaki P., de la Chapelle A., Hamilton S.R., et al., 1995. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 9: 48-55.

Lubbert M., 2000. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 249: 135-164.

Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K., 2001. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 1: 194-202.

Mizuno K., Osada H., Konishi H., Tatematsu Y., Yatabe Y., Mitsu-domi T., Fujii Y., and Takahashi T., 2002. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21: 2328-2333.

Morin P.J., Sparks A.B., KorinekV., Barker N., Clevers H., Vogelstein B., and Kinzler K.W., 1997. Activation of p-catenin-Tcf signaling in colon cancer by mutations in p-catenin or APC Science 275: 1787-1790.

Narayan A., Ji W., Zhang X.Y., Marrogi A., Graff J.R., Baylin S.B., and Ehrlich M., 1998. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer 77: 833-838.

Nemoto S., Fergusson M.M., and Finkel T., 2004. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105-2108.

Nguyen C.T., Gonzales F.A., and Jones P.A., 2001. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: Correlation of accessibility, methylation, MeCP2 binding and acetylation Nucleic Acids Res. 29: 4598-4606.

Pfeifer G.P., Tang M., and Denissenko M.F., 2000. Mutation hotspots and DNA methylation. Curr. Top. Microbiol. Immunol. 249: 1-19.

Rainier S., Johnson L.A., Dobry C.J., Ping A.J., Grundy P.E., and Feinberg A.P., 1993. Relaxation of imprinted genes in human cancer. Nature 362: 747-749.

Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., et al., 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.

Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., Vogelstein B., Baylin S.B., and Schuebel K.E., 2000. CpG methylation is mamtained in human cancer cells lacking DNMT1. Nature 404: 1003-1007.

Richon V.M. and O’Brien J.P., 2002. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8: 662-664.

Rideout W.M., III, Coetzee G.A., Olumi A.F., and Jones P.A., 1990. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288-1290.

Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., and Wolffe A.P., 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25: 338-342.

Romanov S.R., Kozakiewicz B.K., Hoist C.R., Stampfer M.R., Haupt L.M., and Tlsty T.D., 2001. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409: 633-637.

Rountree M.R., Bachman K.E., and Baylin S.B., 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25: 269-277.

Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., and Dryja T.P., 1991. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 48: 880-888.

Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., Carter M.G., de Boom Witzel S., Okano H., Ko M.S., Ohlsson R., Longo D.L., and Feinberg A.P., 2005. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307: 1976-1978.

Silverman L.R., Demakos E.P., Peterson B.L., Komblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro CM., et al., 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J. Clin. Oncol., 20: 2429-2440.

Srinivasan P.R. and Borek E., 1964. Enzymatic alteration of nucleic acid structure. Science 145: 548-553.

Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P, Herman J.G., and Baylin S.B., 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31: 141-149.

Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., et al., 2004. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36: 417-422.

Toyota M., Ho C., Ahuja N., Jair K.W, Li Q., Ohe-Toyota M., Baylin S.B., and Issa J.P., 1999. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59: 2307-2312.

Ushijima T., 2005. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5: 223-231.

Veigl M.L., Kasturi L., Olechnowicz J., MaA.H., LutterbaughJ.D., Periyasamy S., Li G.M., Drummond J., Modnch P.L., Sedwick W.D., and Markowitz S.D., 1998. Biallelic inactivation ofhMLHl by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. 95: 8698-8702.

Wales M.M., Biel M.A., el Deiry W., Nelkin B.D., Issa J.P., Cavenee W.K., Kuerbitz S.J., and Baylin S.B., 1995. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17pl3.3. Nat. Med. 1: 570-577.

Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C, Andre M., and Ferrant A., 2000. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodys-plastic syndrome: A multicenter phase II study in elderly patients. J. Clin. Oncol. 18: 956-962.

Wolf P., Hu Y.C., Doffek K., Sidransky D., and Ahrendt S.A., 2001. 0⁶-methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 61: 8113-8117.

Wolffe A.P., 2001. Chromatin remodeling: Why it is important in cancer. Oncogene, 20: 2988-2990.

Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., Sato R., Meltzer S.J., and Sidransky D., 2002. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495.